Enliven Therapeutics Inc’s filing revealed that its CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P unloaded Company’s shares for reported $0.1 million on May 01 ’25. In the deal valued at $20.07 per share,5,030 shares were sold. As a result of this transaction, Lyssikatos Joseph P now holds 992,658 shares worth roughly $19.55 million.
Then, Lyssikatos Joseph P sold 2,470 shares, generating $49,424 in total proceeds. Upon selling the shares at $20.01, the CHIEF SCIENTIFIC OFFICER now owns 990,188 shares.
Before that, Kintz Samuel sold 5,330 shares. Enliven Therapeutics Inc shares valued at $107,007 were divested by the PRESIDENT AND CEO at a price of $20.08 per share. As a result of the transaction, Kintz Samuel now holds 980,062 shares, worth roughly $19.3 million.
BTIG Research initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on December 13, 2024; the price target was $42. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Robert W. Baird began covering ELVN with “an Outperform” recommendation on June 11, 2024. Mizuho started covering the stock on April 09, 2024. It rated ELVN as “a Buy”.
Price Performance Review of ELVN
On Tuesday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock fall -3.43% to $19.69. Over the last five days, the stock has gained 5.58%. Enliven Therapeutics Inc shares have fallen nearly -12.49% since the year began. Nevertheless, the stocks have fallen -6.19% over the past one year. While a 52-week high of $30.03 was reached on 01/03/25, a 52-week low of $13.30 was recorded on 04/10/25. SMA at 50 days reached $19.40, while 200 days put it at $22.91.
Levels Of Support And Resistance For ELVN Stock
The 24-hour chart illustrates a support level at 18.98, which if violated will result in even more drops to 18.28. On the upside, there is a resistance level at 20.37. A further resistance level may holdings at 21.06. The Relative Strength Index (RSI) on the 14-day chart is 54.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.77, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 20.56%. Stochastics %K at 88.91% indicates the stock is a selling.
The most recent change occurred on March 29, 2023 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
